^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BNT111

    i
    Company:
    BioNTech
    Drug class:
    Immunostimulant, NY ESO 1 inhibitor, MAGE-A3 inhibitor, Protein tyrosine phosphatase inhibitor, Tyrosinase inhibitor
    Related drugs:
    Apply
    Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma (BNT111-01) (NCT04526899)
    Phase 2
    BioNTech SE
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    05/19/2021
    Primary completion :
    01/25/2024
    Completion :
    07/01/2026
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Libtayo (cemiplimab-rwlc) • BNT111
    Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (Lipo-MERIT) (NCT02410733)
    Phase 1
    BioNTech SE
    Completed
    Last update posted :
    07/19/2023
    Initiation :
    03/01/2015
    Primary completion :
    06/20/2023
    Completion :
    06/20/2023
    CTAG1B
    |
    BNT111